关于此电子书
The second edition of this book provides an updated and comprehensive review of the field. The book, which includes many tables and figures, is presented in three main sections: (i) Lipoprotein metabolism, qualitative changes and measurements; (ii) Lipoproteins and the complications of diabetes; and (iii) the treatment of lipoproteins in diabetes. Each chapter from the first edition has been updated, and new topics added. New topics include the links between glycemia and lipoproteins, the role of lipoproteins in ischemic stroke, the diagnosis and management of statin intolerance (which is thought to be more common in people with diabetes) and the use of PCSK9 inhibitors and fish oils in the management of lipoproteins in people with diabetes. This book is written by an international group of experts in the clinical, laboratory and research aspects of lipoproteins in diabetes.
Lipoproteins in Diabetes Mellitus, 2nd Edition is a comprehensive reference on the clinical and scientific aspects of lipoproteins in diabetes. It is a must-have resource for primary care and specialist clinicians, clinical and basic science researchers and to trainees and students.
作者简介
Alicia J. Jenkins, MBBS, MD, FRACP, FRCP
NHMRC Clinical Trials Centre, University of Sydney
Medical Foundation Building Level 6
92-94 Parramatta Rd
Camperdown, Sydney, 2050, NSW, Australia
alicia.jenkins@sydney.edu.au
Peter P. Toth, MD, PhD, FCCP, FESC, FAHA, FACC
Department of Medicine, Division of Cardiology
Johns Hopkins University School of Medicine
Baltimore, Maryland
USA
Peter.toth@cghmc.com
Alicia J. Jenkins, MBBS, MD, FRACP, FRCP is an endocrinologist and researcher. She is a Professor of Diabetes and Vascular Medicine at the University of Sydney, Australia and has honorary academic appointments at Universities in the USA, UK and Hong Kong. Her higher research degree and ongoing clinical and research relates to lipoproteins in diabetes, (clinical, biochemical and molecular) biomarkers, and to the prediction and prevention of the complications of diabetes. She and her research team and collaborators undertake clinical and basic research and clinical trials related to diabetes and its complications and to cardiovascular disease. She is a Chief Investigator on several investigator initiated clinical trials in diabetes, including several related to lipid drugs. She has over 400 publications, cited over 10,000 times and an H-index of 53. Alicia has previously worked with Peter Toth to edit the first edition of Lipoproteins in Diabetes Mellitus. Alicia works clinically in Type 1 diabetes clinics and is currently on the International Diabetes Federation Western Pacific Region Executive Council, co-Director of the Australian Cardiovascular Alliance Precision Medicine Flagship, the Lipid Guidelines Committee for the Australian Diabetes Society and President of the diabetes aid organisation Insulin For Life.
Peter P. Toth, MD, PhD is director of preventive cardiology at the CGH Medical Center in Sterling, Illinois. He is Professor of Clinical Family and Community Medicine at the University of Illinois School of Medicine, Professor of Clinical Medicine at Michigan State University College of Osteopathic Medicine, and Adjunct Associate Professor of Medicine, Division of Cardiology, Johns Hopkins University School of Medicine. Dr. Toth is a past president of the National Lipid Association and American Board of Clinical Lipidology. He is President of the American Society of Preventive Cardiology. Dr. Toth has authored and coauthored over 500 publications in medical and scientific journals and textbooks. He is Series Editor of Springer’s textbook collection in Contemporary Cardiology. He has edited and written 19 textbooks on various aspects of cardiovascular medicine. He has lectured on many topics in cardiovascular medicine throughout the world. His Google Scholar score include 13,125 citations, h-index 58, and i10-index 224.
